Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment

Area of Science:

• Pediatric Dermatology
• Inflammatory Skin Diseases
• Biologic Therapies

Background:

• Psoriasis affects approximately 2% of children globally.
• A subset of pediatric psoriasis patients experience isolated nail disease.
• Nail psoriasis can be disabling and often refractory to topical treatments.

Observation:

• Pediatric nail psoriasis presents a significant clinical challenge.
• Limited treatment options exist for severe or isolated pediatric nail psoriasis.
• Targeted biologic agents are emerging as a therapeutic option.

Findings:

• Biologic agents provide safe and effective treatment for moderate-to-severe pediatric psoriasis, including nail involvement.
• Several biologic therapies are now approved by the Food and Drug Administration (FDA) for pediatric use.
• These agents offer a targeted approach to managing complex pediatric inflammatory skin conditions.

Implications:

• Biologic therapies represent a significant advancement in managing pediatric psoriasis, particularly severe and nail-involved cases.
• Increased FDA approval of biologics for children expands treatment accessibility.
• Further research into long-term efficacy and safety in pediatric populations is warranted.